Brain Cancer

Charlotte Ivey Rivers, MD, discussed the importance of rare CNS tumor research, upcoming trial data in meningioma, and the role of functional radiosurgery.

Findings from a phase 2 study demonstrate the feasibility of conducting genomically driven trials among patients with meningiomas.

The developer now plans to initiate a first-in-human clinical trial among patients with recurrent high-grade glioma.

Researchers have found that engineering CAR T cells to target Tenascin-C, an extracellular matrix protein enriched in glioblastoma, can shrink tumors and prolong survival in preclinical brain tumor models while sparing healthy tissue.

With a median follow-up of 6 months, the median OS was not yet reached in patients with recurrent glioblastoma with the nogapendekin alfa inbakicept-based regimen.

The submission of an investigational new drug application for a uPAR-targeted imaging agent, FG001, supports a planned phase 2 trial in glioma.

Among the 12 patients with suspected brain metastases treated with RAD 101, the images showed metabolic activity in brain metastases compared with MRI findings.

Treatment with IGV-001 demonstrated a 45% increase in overall survival compared with standard of care in patients with newly diagnosed glioblastoma.

Edward Chu, MD, a member of the gastrointestinal editorial advisory board, died of glioblastoma in November.

One patient with newly diagnosed glioblastoma multiforme reached 3 years of survival following treatment with temferon in a phase 1/2a trial.

Data from a phase 1 trial demonstrate the safety and feasibility of administering chlorotoxin-based cellular therapy to those with recurrent glioblastoma.

While more work must be done to minimize toxicity, antibody-drug conjugates have demonstrated benefits for patients with glioblastoma.

Interim data from the phase 1b CLOVER-2 trial evaluating iopofosine I 131 in children and adults with high-grade glioma supported the FDA’s decision.

The evaluation of MT-125’s safety and preliminary activity in glioblastoma is underway in a phase 1/2 trial.

Data from the phase 3 ROADS trial show significant gains in efficacy without increases in safety concerns following the use of GammaTile.

A patient case of a 76-year-old man with a rare glioblastoma variant showcased the importance of molecular profiling in diagnosing and guiding treatment for brain tumors.

Results from a pilot phase 2 trial showed that all 5 patients who received treatment achieved a response or had stable disease.

Historical standards for H3K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.

Dordaviprone was recommended at a dose of 625 mg orally once weekly for adults, and the recommended dosage is based on body weight for pediatric patients.

Extended follow-up for individuals with H3K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.

Supporting data for the accelerated approval of dordaviprone come from 5 open-label trials in H3 K27M-mutant diffuse midline glioma.

Updated guidelines from ASTRO recommend various radiation therapy techniques for patients with WHO grade 4 adult-type diffuse glioma.

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.